Physician profile
John M Carpenter
NPI 1730153412
$1,421.48
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,264 · 2020: $158.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $411.75 | 2019-2020 | |
| Amgen INC. | $189.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $148.76 | 2019-2020 | |
| Amarin Pharma, INC. | $148.27 | 2019-2020 | |
| Novo Nordisk INC | $122.98 | 2019 | |
| Glaxosmithkline, LLC. | $119.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.96 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.05 | 2019-2020 | |
| Pfizer INC. | $44.96 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.08 | 2019 | |
| Genentech USA, INC. | $17.97 | 2019 | |
| Sanofi Pasteur INC. | $15.95 | 2019 | |
| Lilly USA, LLC | $13.15 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.